Crinetics Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is a U.S.-based biopharmaceutical company headquartered in San Diego, California, United States. The company was founded in 2008 by scientists with deep experience in endocrine drug discovery, and it has built its business around internally discovered, small-molecule therapies for endocrine diseases and endocrine-related tumors. Over time, Crinetics has evolved from a clinical-stage developer into a company with a commercial asset, while still maintaining a broad research-and-development pipeline. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1658247/000095017025057467/crnx_ars_2024.pdf?utm_source=openai)) Crinetics’ core business is focused on precision endocrinology. The company develops orally administered, nonpeptide therapies aimed at important hormone-receptor pathways, with programs spanning pituitary disorders, adrenal diseases, and selected neuroendocrine tumors. Its lead product, PALSONIFY™ (paltusotine), reached a major inflection point when it received FDA approval in September 2025 for adult acromegaly, making it the company’s first approved and commercialized therapy. Management also highlights a disclosed pipeline of 10+ programs, including atumelnant, which is being developed for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, as well as CRN09682, a nonpeptide drug conjugate for SST2-expressing tumors. ([crinetics.com](https://crinetics.com/crinetics-announces-fda-approval-of-palsonify-paltusotine-for-the-treatment-of-acromegaly-in-adults/?utm_source=openai)) From a competitive standpoint, Crinetics is positioned as a niche endocrine specialist with a differentiated scientific platform and a strong focus on diseases where treatment options remain limited. That specialization can be attractive in biotech because it supports deep clinical expertise, potentially meaningful pricing power in rare-disease markets, and a clearer path to commercialization in targeted patient populations. The company also disclosed the creation of Crinetics Pharmaceuticals Europe GmbH, signaling an incremental effort to support development, regulatory, and pre-commercial activities outside the United States. ([ir.crinetics.com](https://ir.crinetics.com/news/news-details/2024/EY-ANNOUNCES-SCOTT-STRUTHERS-PH-D--CEO-AND-FOUNDER-OF-CRINETICS-PHARMACEUTICALS-AS-AN-ENTREPRENEUR-OF-THE-YEAR-2024-PACIFIC-SOUTHWEST-AWARD-WINNER-06-18-2024/default.aspx?utm_source=openai)) Recent company updates underscore a business in transition. During 2025 and 2026, Crinetics reported continued launch execution for PALSONIFY, further advancement of atumelnant in clinical development, and progress across late-stage programs in CAH and other endocrine indications. The company also completed a public equity offering in 2026 to support commercial launch activities and R&D, reinforcing its capital-intensive profile. For French, Belgian, and Swiss investors, CRNX is therefore a NASDAQ-listed U.S. healthcare name with a mix of commercial potential and classic biotech risks, including regulatory execution, clinical readouts, manufacturing dependence, and funding needs. ([crinetics.com](https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update/?utm_source=openai))